In the expanded cohort, 3 of 5 ALCL patients (3 ALK+ and 2 ALK-) carrying FAT4 substitutions at high VAF had truncating or damaging variants in highly conserved residues (Supplementary Table S4). The gene discussed is FAT4; the disease is anaplastic large cell lymphoma.